Abortion providers, clinics and abortion rights advocates and patients are anticipating a US Supreme Court decision that could provide some clarity about the fate of a widely used drug at the centre of the biggest legal battle for abortion care since the fall of Roe v Wade last year.
A federal appeals court partially blocked a ruling from a Donald Trump-appointed federal judge in Texas that would strip mifepristone’s approval from the US Food and Drug Administration, which has been in place for more than two decades.
